For years, millions of women have been told they have polycystic ovary syndrome (PCOS). In May 2026, following an international consensus process involving healthcare professionals, researchers, professional societies and people with lived experience, the condition was officially renamed polyendocrine metabolic ovarian syndrome (PMOS).
At first glance, it might seem like just a new acronym. But this is not simply a rebrand, it represents a major shift in how one of the world’s most common hormonal disorders is understood, diagnosed and managed.
The old name, polycystic ovary syndrome, has always been misleading.
Despite the name:
In fact, many women spend years undiagnosed because healthcare professionals, and patients themselves, may believe ovarian cysts are required for diagnosis.
The new name, polyendocrine metabolic ovarian syndrome, better reflects what research has shown for decades: this is a complex disorder involving multiple hormone systems, metabolism and reproductive health, not simply the ovaries. International experts hope the change will reduce confusion, support earlier diagnosis and encourage more comprehensive care.
Let’s break it down.
“Endocrine” refers to the body’s hormone-producing glands.
PMOS affects several hormonal systems simultaneously, including:
Rather than being solely an ovarian disease, PMOS is now recognised as a whole-body endocrine condition.
This is arguably the biggest addition and one of the most important.
Research consistently shows that insulin resistance is common in PMOS and can occur across different body sizes. Insulin resistance means the body’s cells do not respond effectively to insulin, causing the pancreas to produce more.
Higher insulin levels can:
This metabolic component has often been overlooked despite being central to the condition.
The ovaries are still involved because hormone imbalances can disrupt ovulation and menstrual cycles.
However, ovarian changes are only one piece of a much larger puzzle.
Many people first learn about the condition when they are struggling to conceive.
But fertility is only one aspect.
PMOS can affect:
It is estimated to affect around one in eight women worldwide, making it one of the most common endocrine disorders affecting women.
One of the biggest misconceptions is that PMOS is purely a reproductive condition.
In reality, insulin can sit at the centre of many symptoms.
When insulin remains elevated:
This helps explain why addressing metabolic health, not just reproductive symptoms, is increasingly recognised as a cornerstone of treatment.
The name change also reflects a broader shift in treatment.
Rather than focusing solely on regulating periods or prescribing the contraceptive pill, experts increasingly recommend a personalised approach that considers:
For some people, medications such as metformin may be appropriate. GLP-1 receptor agonists may also be considered for selected individuals with obesity or significant metabolic risk. Treatment should always be individualised and discussed with a qualified healthcare professional.
The answer is reassuring.
The condition itself has not changed, only the name used to describe it.
Healthcare professionals are expected to adopt the new terminology gradually as clinical guidelines, healthcare systems, medical records and educational resources are updated. During this transition, many clinicians and organisations may use the wording “PMOS, formerly known as PCOS”.
NICE has already adopted PMOS in the title and recommendations of its developing guideline, while noting that older supporting documents may continue to use PCOS during the transition.
Changing the name from PCOS to PMOS is not about creating a new condition.
It is about recognising more accurately what science has shown for years.
PMOS is not simply an ovarian disorder.
It is a complex endocrine and metabolic condition that can influence hormone balance, insulin function, reproductive health, mental wellbeing and long-term health throughout life.
By moving away from a misleading name, researchers and healthcare organisations hope that more women will be diagnosed earlier, receive more personalised care and better understand that their symptoms are connected.
Because when we name a condition more accurately, we improve the chances of recognising and treating it more effectively.
© 2026 Biomel. All rights reserved.
* Biomel contains billions of live active cultures and Vitamins B6 to support normal energy-yielding metabolism, normal functioning of the nervous system, normal psychological function, reduction of tiredness and fatigue and the regulation of hormonal activity, Vitamin D to support the normal function of the immune system and Calcium to support the normal function of digestive enzymes. Chicory root fibre contributes to normal bowel function by increasing stool frequency. Biomel Complete Gut contains 3g of chicory root fibre per serving. Full beneficial effect is obtained with a daily intake of 12g chicory root fibre.
** Consumer experiences are one person’s experience and may not reflect the experience of all users. Individual results may vary. Testimonials are only from verified customers.
*** Biomel is formulated using ingredients supported by over 300 published scientific studies.
Our products are not intended to diagnose, treat, cure, or prevent any disease.
The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional.
